Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 31, 2008, Pages 10978-10983

  Chan, W Y ^a   McKinzie, D L ^a   Bose, S ^a   Mitchell, S N ^a   Witkin, J M ^a   Thompson, R C ^a   Christopoulos, A ^b   Lazareno, S ^c   Birdsall, N J M ^d   Bymaster, F P ^a   Felder, C C ^a  

^a ELI LILLY AND COMPANY   (United States)

^b MONASH UNIVERSITY   (Australia)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Cholinergic; Cooperativity; GPCR

Indexed keywords

AMINO ACID; CHOLINERGIC RECEPTOR; LY 2033298; METHYLSCOPOLAMINE; MUSCARINIC M4 RECEPTOR; NEUROLEPTIC AGENT; OXOTREMORINE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; SCHIZOPHRENIA;

ALLOSTERIC REGULATION; ANTIPSYCHOTIC AGENTS; CELL LINE; DNA MUTATIONAL ANALYSIS; HUMANS; NICOTINIC ACIDS; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M4; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; THIOPHENES;

ANIMALIA;

EID: 49449108109     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0800567105     Document Type: Article

References (47)

1. Jablensky A (2006) Subtyping schizophrenia: Implications for genetic research. Mol Psychiatry 11:815-836.
2. Lindsley CW, et al. (2006) Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem 6(8):771-785.
3. Tamminga CA (2006) The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67(Suppl. 9):9 -13.
4. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
5. Felder CC, Bymaster FP, Ward J, DeLapp N (2000) Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 43(23):4333-4353.
6. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B (2007) Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 12:232-246.
7. De Luca V, et al. (2004) Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology 50:124-127.
8. Liao D-L, et al. (2003) Association of muscarinic M1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 48:72-76.
9. Bodick NC, et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465-473.
10. Ellis JR, et al. (2006) Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacology 9:175-189.
11. Minzenberg MJ, Poole JH, Benton C, Vinogradov S (2004) Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 161:116-124.
12. Mirza NR, Peters D, Sparks RG (2003) Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 9:159-186.
13. Raedler TJ, Tandon R (2006) Cholinergic mechanisms in schizophrenia: Current concepts. Curr Psychosis Therapeutics Rep 4(1):20-26.
14. Medina A, Bodick N, Goldberger AL, Mac Mahon M, Lipsitz LA Effects of central muscarinic-1 receptor stimulation on blood pressure regulation Hypertension 29:828-834, 1997.
15. Yasuda RP, et al. (1993) Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: Distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 43:149-157.
16. Wirtshafter D, Osborn CV (2004) The distribution of m4 muscarinic acetylcholine receptors in the islands of Calleja and striatum of rats and cynomolgus monkeys. J Chem Neuroanatomy 28:107-116 and erratum (2005) 29(3):227.
17. Bymaster FP, McKinzie DL, Felder CC, Wess J (2003) Use of M-1-M-5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 28:437-442.
18. Tzavara ET, et al. (2004) M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: Relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 18:1410-1412.
19. Lu ZL, Saldanha JW, Hulme EC (2002) Seven-transmembrane receptors: Crystals clarify. Trends Pharmacol Sci 23:140-146.
20. Eglen RM (2005) Muscarinic receptor subtype pharmacology and physiology. Progress Med Chem 43:105-136.
21. Birdsall NJ, Lazareno S (2005) Allosterism at muscarinic receptors: Ligands and mechanisms. Mini Rev Med Chem 5:523-543.
22. Christopoulos A, Lanzafame A, Mitchelson F (1998) Allosteric interactions at muscarinic cholinoceptors. Clin Exp Pharmacol Physiol 25:185-194.
23. Birdsall NJ, et al. (1999) Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: Functional studies. Mol Pharmacol 55:778-786.
24. Christopoulos A, Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
25. Watson J, et al. (1998) Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol 125:1413-1420.
26. Rasmussen T, et al. (2001) The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance. Schizophrenia Res 49:193-201.
27. Bymaster FP, et al. (1998) Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4- yl)-1-azabicyclo[3.2.1]octane. Eur J Pharmacol 356:109-119.
28. Ferreira AR, et al. (2003) Role of hippocampal M1 and M4 muscarinic receptor subtypes in memory consolidation in the rat. Pharmacol Biochem Behav 74:411-415.
29. McKinney M (2005) Brain cholinergic vulnerability: Relevance to behavior and disease. Biochem Pharmacol 70(8):1115-1124.
30. 4 muscarinic receptors. Life Sci 64:519-526.
31. Lazareno S, Dolezal V, Popham A, Birdsall NJ (2004) Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: Receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol 65:257-266.
32. Jakubik J, Bacakova L, El-Fakahany EE, Tucek S (1997) Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52:172-179.
33. May LT, Leach K, Sexton PM, Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
34. Leach K, Sexton PM, Christopoulos A (2007) Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389.
35. Wess J (2005) Allosteric binding sites on muscarinic acetylcholine receptors. Mol Pharmacol 68:1506-1509.
36. Jakubik J, Krejci A, Dolezal V (2005) Asparagine, valine, and threonine in the third extracellular loop of muscarinic receptor have essential roles in the positive cooperativity of strychnine-like allosteric modulators. J Pharmacol Exp Ther 313:688-696.
37. Krejci A, Tucek S (2001) Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol Pharmacol 60:761-767.
38. Gnagey AL, Seidenberg M, Ellis J (1999) Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. Mol Pharmacol 56:1245-1253.
39. Huang XP, Prilla S, Mohr K, Ellis J (2005) Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: More similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3- phthalimidopropyl)ammonium]dibromide. Mol Pharmacol 68:769-778.
40. Sawa A, Snyder SH (2002) Schizophrenia: Diverse approaches to a complex disease. Science 296:692-695.
41. DeLeon A, Patel NC, Crismon ML (2004) Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666.
42. Patil ST, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 13:1102-1107.
43. Matsumoto I, Inoue Y, Iwazaki T, Pavey G, Dean B (2005) 5-HT2A and muscarinic receptors in schizophrenia: A postmortem study. Neurosci Lett 379(3):64-168.
44. Scarr E, Sundram S, Keriakous D, Dean B (2007) Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 61:1161-1170.
45. Lazareno S, Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
46. DeLapp NW, et al. (1999) Determination of [S-35]guanosine- 5′-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. J Pharmacol Exp Ther 289:946-955.
47. Rorick-Kehn LM, et al. (2007) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 193:121-136.